Reverse Takeover in South Korea.
How a private company in South Korea can go public in the United States by reverse takeover into a clean Nasdaq, NYSE American or OTC shell — and the home-market considerations that shape the transaction.
South Korea pairs a world-scale industrial base with one of Asia's most active retail equity cultures. The Korea Exchange runs two boards — KOSPI for established large-caps and KOSDAQ for technology and growth names — yet many founders in semiconductors, digital content and life sciences build ambitions that outrun a won-denominated quote. Because the currency is not fully internationalised and global funds increasingly price Korean technology on US comparables, a reverse takeover into a clean Nasdaq, NYSE American or OTC shell has become a credible way to reach dollar capital and an international shareholder register.
- Outbound investment and overseas-entity establishment generally require Foreign Exchange Transaction Act reporting to a designated FX bank, with some matters escalating further.
- Won is not fully convertible, so cash repatriation, dividend flows and share-swap mechanics need to be planned with FX counsel.
- K-IFRS reporting helps, but a PCAOB-registered audit — typically two years — remains the critical-path item.
- Contributing founder shares into an offshore holding company can trigger Korean tax; model the cost before committing to a structure.
- Ongoing US reporting, Regulation FD and insider-trading rules apply immediately on listing and differ from Korean disclosure practice.
South Korea at a glance
| Home market | Korea Exchange (KOSPI and KOSDAQ) |
|---|---|
| Home regulator | Financial Services Commission (FSC) |
| Currency | South Korean won (KRW) |
| Notable sectors | Technology and semiconductors, digital content and gaming, biotech, and consumer. |
| US venues | Nasdaq, NYSE American, and the OTC Markets (OTCQX, OTCQB) |
| Our role | Advisory and arranger of the reverse takeover; not a broker-dealer, law firm or auditor. |
Why South Korea companies list in the United States
Korean companies generally look to the United States when their story is understood better by global specialists than by domestic desks. Semiconductor-equipment suppliers, biotech platforms, gaming studios and webtoon or K-content businesses tend to attract US technology and healthcare investors who benchmark them against listed American and Israeli peers, which can support valuations that a purely domestic float may not. A US quote also provides a hard-currency acquisition currency for buying complementary technology abroad, a research following that travels with international mandates, and the profile that helps recruit and retain talent globally. For groups already selling into US supply chains, a US listing keeps capital markets and customers in the same time zone of attention.
The South Korea market and a US listing
KOSDAQ is a genuinely credible growth board, and Korea offers technology-evaluation and special listing routes that suit pre-profit innovators, so a home listing is a real option rather than a fallback. The trade-offs are different, though. Domestic listings run on the Korea Exchange's review calendar and disclosure regime, and secondary-market interest can concentrate on names that fit familiar retail themes. A US reverse takeover generally offers deeper institutional liquidity, sector-specialist coverage and multiples set against global rather than local comparables. Timelines depend on shell quality, diligence and audit readiness rather than a fixed queue, and eligibility is tested against exchange standards — including Nasdaq's US$4.00 minimum bid — instead of a domestic listing committee.
Sectors driving South Korea US listings
Korea's export strengths map neatly onto US public-market appetite. Semiconductor materials, components and equipment sit at the centre of a supply chain American investors follow closely; digital content — gaming, webtoons, music and streaming IP — travels globally and resonates with growth funds; and a deep biotech and medical-device cluster fits the US life-sciences investor base. Consumer names in beauty and premium food also carry recognisable brand equity abroad. Each of these tends to be valued more richly against international comparables than a domestic-only listing would imply, which is much of the reason founders explore a US route.
Cross-border structuring from South Korea
Cross-border deals from Korea are typically built above the operating company using an offshore holding vehicle — commonly a Cayman, BVI or Singapore entity — that becomes the US-listed parent, with careful thought given to how shares in the Korean company are contributed or exchanged. The Foreign Exchange Transaction Act framework is central: outbound investment and the establishment of overseas entities generally require reporting to a designated foreign-exchange bank, with certain matters escalating to the Bank of Korea or the Ministry of Economy and Finance. Won convertibility, transfer pricing on any intra-group licences, and the tax cost of moving founder shares into an offshore holdco all need mapping early. None of this is a do-it-yourself exercise; structuring should be set with Korean and US counsel and tax advisers, subject to current rules and specialist advice.
Audit and reporting readiness
Korea has adopted K-IFRS, so many groups already report on an IFRS basis, which shortens — but does not eliminate — the distance to a US filing. The gating item is almost always an audit by a PCAOB-registered firm, usually of two years of financial statements, prepared or reconciled to the standards a US registrant must meet. Related-party dealings common in Korean group structures, revenue-recognition on multi-element technology contracts, and stock-based compensation tend to draw the most scrutiny. Because assembling audit-ready numbers can take longer than the merger mechanics themselves, engaging the auditor before the shell is selected is the single most useful step.
Choose a US venue
The same South Korea company can target different US venues depending on its size and readiness. Each page below sets out the route and the listing standards.
- Nasdaq listingSouth Korea → Nasdaq
- NYSE American listingSouth Korea → NYSE American
- OTC Markets listingSouth Korea → OTC Markets
Exploring a US listing from Tell us about your company.
Start an enquiry →Reverse Takeover in South Korea — frequently asked questions
Q1Can a company already listed on KOSDAQ also pursue a US reverse takeover?
It can be contemplated, but a dual-listed or cross-border structure raises Korea Exchange, disclosure and Foreign Exchange Transaction Act questions that must be worked through with Korean counsel. The interaction between a domestic listing and a new US-listed holding company is fact-specific and should be planned before any transaction, subject to current rules and specialist advice.
Q2Does Korean law let founders move their shares into an offshore holding company?
Establishing overseas entities and outbound investment generally require reporting under the Foreign Exchange Transaction Act, typically through a designated foreign-exchange bank, with some cases escalating to the Bank of Korea or the Ministry of Economy and Finance. The tax consequences of contributing shares also need modelling. This is a matter for Korean FX and tax specialists, not a step to improvise.
Q3How long does a Korean cross-border reverse takeover generally take?
There is no fixed timetable, and Reverse Takeover does not promise one. In practice the pace is set by audit readiness, diligence and the quality of the chosen shell rather than by a listing queue. Preparing PCAOB-standard financials early is usually what determines whether the process moves efficiently.
Q4Is Reverse Takeover a broker-dealer?
No. Reverse Takeover is an advisory and arranger — not a registered broker-dealer, investment adviser, law firm or audit firm. Regulated work is performed by the US securities counsel, PCAOB-registered auditors and transfer agents we coordinate.
Related markets
This page is general, educational information about listing routes and is not investment, legal, tax, or accounting advice, nor an offer or solicitation. Regulatory details change and vary by circumstance; obtain advice from qualified US securities counsel and your home-market advisers. See our disclosures.